Tempus AI (NASDAQ:TEM) Shares Up 2.8% - What's Next?

Key Points

• Tempus AI shares rose 2.8% during Monday trading, with the stock reaching a high of $83.27 before closing at $81.86.
• Multiple analysts have issued new price targets for Tempus AI, with BTIG Research raising it from $75.00 to $85.00 and maintaining a "buy" rating.
• The company reported a revenue increase of 89.5% year-over-year, reaching $314.64 million, while its EPS for the quarter was ($0.22), exceeding analysts' expectations.

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) traded up 2.8% during trading on Monday . The stock traded as high as $83.27 and last traded at $81.86. 3,990,615 shares traded hands during mid-day trading, a decline of 68% from the average session volume of 12,316,837 shares. The stock had previously closed at $79.62.

Analysts Set New Price Targets

Several equities analysts recently issued reports on TEM shares. Bank of America upped their price objective on Tempus AI from $68.00 to $70.00 and gave the company a "neutral" rating in a research report on Wednesday, June 25th. HC Wainwright assumed coverage on shares of Tempus AI in a report on Tuesday, September 2nd. They issued a "buy" rating and a $90.00 target price on the stock. Needham & Company LLC reaffirmed a "buy" rating and set a $70.00 price target on shares of Tempus AI in a research note on Friday, August 8th. BTIG Research upped their target price on Tempus AI from $75.00 to $85.00 and gave the company a "buy" rating in a research report on Wednesday, August 20th. Finally, Morgan Stanley upped their target price on Tempus AI from $65.00 to $68.00 and gave the company an "overweight" rating in a report on Tuesday, August 12th. Seven research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $69.50.

Tempus AI Trading Up 0.7%

The stock has a 50 day moving average price of $65.39 and a 200 day moving average price of $58.92. The company has a market cap of $13.93 billion, a PE ratio of -67.07 and a beta of 5.07. The company has a current ratio of 1.54, a quick ratio of 1.43 and a debt-to-equity ratio of 2.58.

Tempus AI (NASDAQ:TEM - Get Free Report) last released its earnings results on Friday, August 8th. The company reported ($0.22) EPS for the quarter, topping analysts' consensus estimates of ($0.23) by $0.01. The company had revenue of $314.64 million during the quarter, compared to analysts' expectations of $296.84 million. Tempus AI had a negative net margin of 20.98% and a negative return on equity of 122.86%. Tempus AI's revenue for the quarter was up 89.5% on a year-over-year basis. During the same period last year, the business earned ($6.86) EPS. Tempus AI has set its FY 2025 guidance at EPS. Sell-side analysts predict that Tempus AI, Inc. will post -6.15 EPS for the current fiscal year.

Insider Buying and Selling at Tempus AI

In other Tempus AI news, CFO James William Rogers sold 7,528 shares of the business's stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $74.65, for a total value of $561,965.20. Following the transaction, the chief financial officer owned 138,473 shares of the company's stock, valued at approximately $10,337,009.45. The trade was a 5.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Ryan Fukushima sold 17,460 shares of the firm's stock in a transaction that occurred on Tuesday, August 19th. The shares were sold at an average price of $74.65, for a total value of $1,303,389.00. Following the completion of the transaction, the chief operating officer owned 839,180 shares of the company's stock, valued at approximately $62,644,787. This represents a 2.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,108,951 shares of company stock valued at $77,660,938 in the last quarter. 26.27% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Tempus AI

Hedge funds have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. raised its stake in shares of Tempus AI by 0.7% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 33,757 shares of the company's stock worth $2,145,000 after buying an additional 226 shares during the last quarter. Marex Group plc acquired a new stake in shares of Tempus AI in the 2nd quarter valued at approximately $26,620,000. Pitcairn Co. bought a new position in Tempus AI in the second quarter valued at about $317,000. Tyler Stone Wealth Management increased its position in shares of Tempus AI by 10.0% during the second quarter. Tyler Stone Wealth Management now owns 8,800 shares of the company's stock worth $559,000 after acquiring an additional 800 shares in the last quarter. Finally, Nomura Holdings Inc. boosted its position in shares of Tempus AI by 116.6% during the 2nd quarter. Nomura Holdings Inc. now owns 45,860 shares of the company's stock valued at $2,914,000 after acquiring an additional 24,689 shares during the last quarter. Hedge funds and other institutional investors own 24.22% of the company's stock.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.